Condition (MeSH)
Coxsackievirus Infections
ClinicalTrials.gov lists 66 trials for Coxsackievirus Infections or a narrower condition beneath it. Sinovac Biotech Co., Ltd has the most among industry and government lead sponsors, with 20.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
7 of the 66 trials are tagged with Coxsackievirus Infections itself; the rest are tagged with a narrower condition beneath it.
When did Coxsackievirus Infections trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 3 |
| 2020 | 3 |
| 2019 | 10 |
| 2018 | 5 |
| 2017 | 6 |
| 2016 | 4 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Coxsackievirus Infections trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 12 |
| Phase 1/2 | 3 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 8 |
| Phase 4 | 16 |
| Not applicable | 10 |
| Observational | 11 |
How many Coxsackievirus Infections trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Completed | 43 |
| Unknown status | 15 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Coxsackievirus Infections trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Sinovac Biotech Co., Ltd | 20 |
| Jiangsu Province Centers for Disease Control and Prevention | 7 |
| Enimmune Corporation | 3 |
| HK inno.N Corporation | 2 |
| Viralytics | 2 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| EV71 Vaccine | 9 |
| Western therapy | 6 |
| 640Eu/0.5ml in children | 2 |
| Enterovirus Type 71 Vaccine (Vero Cell), Inactivated | 2 |
| 0Eu/0.5ml in infants | 2 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Coxsackievirus Infections? (19)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021 | Yes |
| Mouse Models of Virus-Induced Type 1 Diabetes. | Methods in molecular biology (Clifton, N.J.) | 2020 | Yes |
| A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. | Diabetologia | 2018 | Yes |
| Persistent mammalian orthoreovirus, coxsackievirus and adenovirus co-infection in a child with a primary immunodeficiency detected by metagenomic sequencing: a case report. | BMC infectious diseases | 2018 | Yes |
| CTLA4-Ig relieves inflammation in murine models of coxsackievirus B3-induced myocarditis. | The Canadian journal of cardiology | 2012 | Yes |
Showing 5 of 19 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.